NCT06788236 is a Phase 2 clinical trial of AVTR101 in Sarcopenia, sponsored by Aventi Biotechnology Inc..

Who is sponsoring NCT06788236?

NCT06788236 is sponsored by Aventi Biotechnology Inc..

What drugs are being tested in NCT06788236?

Interventions in NCT06788236: AVTR101, Placebo.

What condition does NCT06788236 study?

NCT06788236 studies Sarcopenia.

Is NCT06788236 still recruiting?

NCT06788236 is currently terminated. Last updated 9 April 2025.

Last reviewed 2025-04-09 · How we verify

NCT06788236

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of Efficacy and Safety of AVTR101 in Sarcopenic Elderly

Terminated Phase 2 Last updated 9 April 2025

What this trial tests

Phase 2 trial testing AVTR101 in Sarcopenia in 100 participants. Terminated before completion.

Timeline

23 May 2022

Primary endpoint
14 June 2024

19 September 2024

Quick facts

Lead sponsor	Aventi Biotechnology Inc.
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	100
Start date	23 May 2022
Primary completion	14 June 2024
Estimated completion	19 September 2024
Sites	4 locations across South Korea

Drugs / interventions tested

AVTR101 — full drug profile →
Placebo

Conditions studied

Sarcopenia — all drugs for Sarcopenia →

Sponsor

Aventi Biotechnology Inc. — full company profile →

Who can join

65 and older, any sex, with Sarcopenia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to primarily evaluate the efficacy of AVTR101 to placebo on physical performance in sarcopenia patients. Participants will: Take AVTR101 or a placebo three times daily for 12 weeks Visit the clinic once every 4 weeks for checkups and tests

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Sarcopenia and Muscle Aging: Updated Insights into Molecular Mechanisms and Translational Therapeutics.
Nguyen TT, Dao T, Nguyen HT, Park JH, et al · · 2026 · cited 1× · PMID 41674227 · DOI 10.3803/enm.2025.2656

Verify or expand the search:

Other recruiting trials for Sarcopenia

Currently open trials in the same condition.

NCT07500376 — Multimodal Nutritional and Sarcopenia Assessment for Risk Stratification in Lung Cancer Surgery · recruiting
NCT07456956 — HIIT vs MCIT for Stroke-Related Sarcopenia in Ischemic Stroke · NA · recruiting
NCT07398495 — Multimodal Training Effects in Middle-Aged and Older Adults With Diabetic Sarcopenia · NA · recruiting
NCT07494916 — Effects of Functional Task Training on Muscle Health and Function in Older Adults With Sarcopenia · NA · active not recruiting
NCT07426159 — AI-Guided Sarcopenia Risk Assessment and Detection · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06788236 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Aventi Biotechnology Inc.
Last refreshed: 9 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06788236.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing